ClinicalTrials.gg

Program

Fuling Yunhua Granules

Its studies are mostly in Diabetes Mellitus, Type 2, led by Beijing Supreme Life Pharmaceutical Technology.

Furthest: phase 2, since Aug 19, 20243 company-led studies, 2 open or runningNext primary completion: Jan 15, 2028 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Beijing Supreme Life Pharmaceutical Technology32 open or runningphase 2since Aug 19, 2024Aug 19, 2024Jan 15, 2028phase 2 · NCT07929350

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Aug 19, 2024First study: phase 2 study in Diabetes Mellitus, Type 2First studyNCT06575478 · 95 enrolled · China
  2. Oct 28, 20262 phase 2 studies in Diabetes Mellitus, Type 2NCT07929350, NCT07920640

Ahead

  1. Jan 15, 2028Primary completion: phase 2 study in Diabetes Mellitus, Type 2NCT07929350
  2. Jan 15, 2028Primary completion: phase 2 study in Diabetes Mellitus, Type 2NCT07920640

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 3 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07929350Diabetes Mellitus, Type 2 · China2Not yet recruitingJan 15, 2028150
NCT07920640Diabetes Mellitus, Type 2 · China2Not yet recruitingJan 15, 2028150
NCT06575478Diabetes Mellitus, Type 2 · China2CompletedJan 27, 202595

How it is read

Names in the registry

  • “Fuling Yunhua Granules”, 3 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.